<DOC>
	<DOCNO>NCT02853539</DOCNO>
	<brief_summary>Low bone mineral density ( BMD ) commonly report patient receive home parenteral nutrition ( HPN ) . Denosumab represent new drug , help prevent osteoclast . The aim study ass value chronic intestinal failure patient .</brief_summary>
	<brief_title>Denosumab Metabolic Bone Disease Chronic Intestinal Failure Patients</brief_title>
	<detailed_description>Low bone mineral density ( BMD ) commonly report patient receive home parenteral nutrition ( HPN ) . Oral intravenous calcium , vitamin D bisphosphonates commonly use treat BMD , efficiency may inadequate due limited absorption compliance . Denosumab represent new drug , help prevent osteoclast development activation , hence decrease bone resorption study . The aim study ass value chronic intestinal failure patient receive HPN . Between November 2011 March 2013 denosumab administer 16 HPN patient ( 9 F , 7 M mean age 55.4 ) intestinal failure . Regional dual-energy x-ray absorptiometry spine hip perform therapy initiate , 12 month . BMD , T-score Z-score measure .</detailed_description>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>intestinal failure require home parental nutrition bone disease measurement intestinal failure require HPN diagnostic modality impossible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>